CombiMatrix said today that it will provide miscarriage analysis to American Pathology Partners' (AP2) physician customers using its chromosomal microarray analysis platform.
AP2 is a nationwide network of anatomic pathology laboratories with a focus on women's health. CombiMatrix said it has commenced working with Denver-based UniPath, AP2's flagship lab.
AP2 CEO Sami Abassi said in a statement that AP2 partnered with CombiMatrix to "provide the best patient care possible," noting that CombiMatrix "specializes in CMA and has become a leader in the [product of conception] testing market."
According to CombiMatrix CEO Mark McDonough, the company's offering for miscarriage analysis is its "fastest-growing test in terms of volumes." McDonough added that such partnerships are an "important part of our growth strategy," and that his company will work with AP2 to "extend our customer base to the nation's leading pathologists."
CombiMatrix announced similar partnerships focused on miscarriage analysis with ProPath in January, and Manhattan Labs last August.
As BioArray News reported last month, CombiMatrix has seen an uptick in product of conception testing volumes since the American Congress of Obstetricians and Gynecologists and the Society of Maternal Fetal-Medicine in December recommended CMA as the preferred test for identifying the cause of death in stillbirths.